Acura Targets 4 Rivals Over Generic Oxecta Plans

Law360, New York (November 1, 2012, 5:22 PM EDT) -- Acura Pharmaceuticals Inc. hit four rivals with patent infringement suits in Delaware federal court Wednesday, seeking to block their plans to market generic versions of opioid painkiller Oxecta.

According to the suits, which target Impax Laboratories Inc., Par Pharmaceutical Inc., Sandoz Inc. and several units of Watson Laboratories Inc., the companies’ abbreviated new drug applications for 5- and 7.5-milligram dosage strength versions of generic oxycodone hydrochloride infringe a patent for Oxecta, an abuse-resistant version of the opioid painkiller.

“Acura will be substantially and irreparably harmed by...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Acura Pharmaceuticals Inc. v. Impax Laboratories Inc.


Case Number

1:12-cv-01371

Court

Delaware

Nature of Suit

Patent

Judge

Richard G. Andrews

Date Filed

October 31, 2012


Case Title

Acura Pharmaceuticals Inc. v. Par Pharmaceutical Inc.


Case Number

1:12-cv-01372

Court

Delaware

Nature of Suit

Patent

Judge

Richard G. Andrews

Date Filed

October 31, 2012


Case Title

Acura Pharmaceuticals Inc. v. Sandoz Inc.


Case Number

1:12-cv-01373

Court

Delaware

Nature of Suit

Patent

Judge

Richard G. Andrews

Date Filed

October 31, 2012


Case Title

Acura Pharmaceuticals Inc. v. Watson Laboratories Inc.-Florida et al


Case Number

1:12-cv-01374

Court

Delaware

Nature of Suit

Patent

Judge

Richard G. Andrews

Date Filed

October 31, 2012

Law Firms

Companies

Government Agencies

Patents

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.